Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• Systolic blood pressure is a significant predictor of mortality from cardiovascular diseases and all causes.
• Angiotensin II (AII) plays a key role in the pathogenesis of systolic hypertension, contributing to arterial wall stiffening and remodeling.
• AII antagonists may offer benefits beyond blood pressure reduction, targeting age-related vascular damage.

Purpose of the Study:

• To evaluate the cardiovascular outcomes benefits of AII antagonists, specifically losartan, in patients with isolated systolic hypertension (ISH).
• To assess the efficacy and tolerability of losartan in managing ISH and associated vascular damage.

Main Methods:

• The study reviewed recent evidence and clinical data on the use of losartan in patients with ISH.
• Analysis focused on cardiovascular outcomes, blood pressure control, and vascular effects associated with AII antagonism.

Main Results:

• Losartan demonstrated cardiovascular outcomes benefits in patients with ISH.
• AII antagonists, including losartan, facilitate systolic blood pressure control in ISH.
• Losartan showed an excellent tolerability profile in the studied population.

Conclusions:

• AII antagonists offer significant cardiovascular protection in patients with ISH.
• Losartan provides a favorable risk-benefit profile for managing ISH and its vascular consequences.
• Targeting the AII pathway is crucial for addressing age-related vascular damage and improving outcomes in systolic hypertension.